Skip to main content

. 1997 Mar;62(3):290–291. doi: 10.1136/jnnp.62.3.290-a

Distribution of tenascin in human malignant gliomas is not related to cell proliferation.

P Castellani, A Siri, L Zardi, A Barbanera, A Dorcaratto, G Viale

PMCID: PMC1064166 PMID: 9069492

290

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Balza E., Siri A., Ponassi M., Caocci F., Linnala A., Virtanen I., Zardi L. Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Lett. 1993 Oct 11;332(1-2):39–43. doi: 10.1016/0014-5793(93)80479-e. [DOI] [PubMed] [Google Scholar]
Castellani P., Dorcaratto A., Siri A., Zardi L., Viale G. L. Tenascin distribution in human brain tumours. Acta Neurochir (Wien) 1995;136(1-2):44–50. doi: 10.1007/BF01411434. [DOI] [PubMed] [Google Scholar]
Paganelli G., Magnani P., Zito F., Lucignani G., Sudati F., Truci G., Motti E., Terreni M., Pollo B., Giovanelli M. Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin. Eur J Nucl Med. 1994 Apr;21(4):314–321. doi: 10.1007/BF00947966. [DOI] [PubMed] [Google Scholar]
Riva P., Arista A., Sturiale C., Moscatelli G., Tison V., Mariani M., Seccamani E., Lazzari S., Fagioli L., Franceschi G. Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2. Int J Cancer. 1992 Apr 22;51(1):7–13. doi: 10.1002/ijc.2910510103. [DOI] [PubMed] [Google Scholar]
Riva P., Arista A., Tison V., Sturiale C., Franceschi G., Spinelli A., Riva N., Casi M., Moscatelli G., Frattarelli M. Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors. Cancer. 1994 Feb 1;73(3 Suppl):1076–1082. doi: 10.1002/1097-0142(19940201)73:3+<1076::aid-cncr2820731347>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES